Paper Details

  1. Home
  2. Paper Details

Rimantadine for treatment of hepatitis C infection in liver transplant recipients.

Author: Aranda-MichelJ, HantoD, MartinS, ShermanK E, SicklerJ, WeberF L, WhitingJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This pilot study evaluated the antiviral activity of rimantadine against hepatitis C virus (HCV) in patients with recurrent post-liver transplantation disease. Rimantadine did not show significant antiviral activity and is not recommended for the management of recurrent hepatitis C after liver transplantation.
Paper Details　
Original Abstract of the Article :
Hepatitis C recurrence after liver transplantation is a serious problem, leading to increased graft loss and morbidity in some individuals. Treatment with interferon and other agents is controversial and not highly efficacious. The use of an effective antiviral agent to reduce or eliminate viral bur...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/lt.500050103

データ提供：米国国立医学図書館（NLM）

Rimantadine for Hepatitis C: A Quest for Effective Treatment in Liver Transplant Recipients

The world of [hepatitis C] is a complex landscape, with the virus often posing significant challenges, especially for individuals who have undergone [liver transplantation]. This study explores the potential of rimantadine, an antiviral drug, to treat recurrent hepatitis C infection in post-transplantation patients, a group that often faces difficulties with conventional therapies.

The Search for a Solution: Rimantadine's Lack of Efficacy in Hepatitis C Recurrence

The study found that rimantadine monotherapy was not effective in reducing or eliminating viral burden in patients with recurrent post-transplantation hepatitis C. This finding highlights the need for alternative treatment strategies for this challenging patient population.

New Avenues of Research: Exploring Combinations and Personalized Therapies

The study's results underscore the importance of exploring novel treatment approaches for recurrent hepatitis C after liver transplantation. This could include investigating combination therapies or developing personalized treatment strategies tailored to the specific needs of each patient.

Dr.Camel's Conclusion

The search for effective treatments for hepatitis C is a journey with many twists and turns. This study underscores the need for ongoing research to find innovative solutions for patients with this debilitating disease. Just as a desert explorer seeks a hidden oasis, researchers continue their quest for treatments that can effectively combat hepatitis C and improve the lives of affected individuals.

Date :
  1. Date Completed 1999-02-11
  2. Date Revised 2019-11-02
Further Info :

Pubmed ID

9873088

DOI: Digital Object Identifier

10.1002/lt.500050103

Related Literature

Article Analysis
・Side Effects of rimantadine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.